Literature DB >> 6706734

Patterns of care outcome studies: results of the national practice in adenocarcinoma of the prostate.

S A Leibel, G E Hanks, S Kramer.   

Abstract

The Patterns of Care Study reviewed the processes and outcome of 682 patients with carcinoma of the prostate treated with radiation therapy from 1973-1976. The study and patient sampling were designed to reflect a valid representation of how prostate cancer is treated by radiation oncologists in the United States. The outcome results represent national benchmarks. The three year actuarial survival was 91% for Stage A, 88% for Stage B, and 76% for Stage C. The three year relapse free survival rate was 85% for Stage A, 77% for Stage B, and 59% for Stage C. The infield recurrence rates were: Stage A--4%, Stage B--9%, and Stage C--20%. Stage, grade, elevated serum acid phosphatase, Karnofsky performance status, previous hormonal therapy, age, and prior transurethral resection were identified by multivariate regression analysis to be important independent prognostic variables. Local control was related to the dose of the primary site, paraprostatic region, and pelvic sidewall. Local control was significantly improved if the facility's best treatment equipment was a linear accelerator. Major complications occurred in 9% of patients with Stage A, 2% of Stage B, and 6% with Stage C disease. Complications were related to dose and treatment technique. The Patterns of Care Process Survey identified that only 60% of patients surveyed had the necessary pretreatment evaluation studies required for best current management of adenocarcinoma of the prostate. Variance occurred within each stratum of facilities sampled. Strict attention to the details of evaluation of therapy will help to enhance the delivery of optimal radiation therapy in the management of patients with carcinoma of the prostate.

Entities:  

Mesh:

Year:  1984        PMID: 6706734     DOI: 10.1016/0360-3016(84)90061-0

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.

Authors:  Xiaohua Ni; Yonggang Zhang; Judit Ribas; Wasim H Chowdhury; Mark Castanares; Zhewei Zhang; Marikki Laiho; Theodore L DeWeese; Shawn E Lupold
Journal:  J Clin Invest       Date:  2011-05-09       Impact factor: 14.808

Review 2.  Complications of radiation therapy and factors in their prevention.

Authors:  J D Cox; R W Byhardt; J F Wilson; J S Haas; R Komaki; L E Olson
Journal:  World J Surg       Date:  1986-04       Impact factor: 3.352

Review 3.  The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer.

Authors:  P T Scardino
Journal:  Trans Am Clin Climatol Assoc       Date:  2000

4.  High-dose-rate brachytherapy combined with long-term hormonal therapy for high-risk prostate cancer: results of a retrospective analysis.

Authors:  Ryoong-Jin Oh; Yasuo Yoshioka; Eiichi Tanaka; Hiroya Shiomi; Iori Sumida; Fumiaki Isohashi; Osamu Suzuki; Koji Konishi; Yoshifumi Kawaguchi; Satoaki Nakamura; Masahiro Kato; Takehiro Inoue
Journal:  Radiat Med       Date:  2006-01

5.  Effects of pretreatment transurethral resection on survival in prostatic carcinoma.

Authors:  J P Austin; H Aziz; L Potters; J Oshelfski; K Choi; M Rotman
Journal:  J Natl Med Assoc       Date:  1994-11       Impact factor: 1.798

6.  Intra-fractional uncertainties in image-guided intensity-modulated radiotherapy (IMRT) of prostate cancer.

Authors:  Buelent Polat; Iris Guenther; Juergen Wilbert; Joachim Goebel; Reinhart A Sweeney; Michael Flentje; Matthias Guckenberger
Journal:  Strahlenther Onkol       Date:  2008-12-24       Impact factor: 3.621

7.  Prostate cancer: results of external irradiation.

Authors:  E K Reddy; L Krishnan; S Giri; R G Evans; W K Mebust; J W Weigel
Journal:  J Natl Med Assoc       Date:  1993-02       Impact factor: 1.798

8.  Distinct effects of rectum delineation methods in 3D-conformal vs. IMRT treatment planning of prostate cancer.

Authors:  Matthias Guckenberger; Jürgen Meyer; Kurt Baier; Dirk Vordermark; Michael Flentje
Journal:  Radiat Oncol       Date:  2006-09-06       Impact factor: 3.481

9.  [The conformal radiotherapy of localized prostatic carcinoma: acute tolerance and early efficacy].

Authors:  D Zierhut; M Flentje; G Sroka-Perez; V Rudat; R Engenhart-Cabillic; M Wannenmacher
Journal:  Strahlenther Onkol       Date:  1997-02       Impact factor: 4.033

10.  Centralised treatment, entry to trials and survival.

Authors:  C A Stiller
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.